AN ECONOMIC EVALUATION OF CABOZANTINIB VS. EVEROLIMUS IN THE SECOND-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

被引：0
|
作者：
Hart, L. A. [1 ]
Carlson, J. J. [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN135
引用
收藏
页码：A111 / A111
页数：1
相关论文
共 50 条
  • [11] Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland
    Purmonen, Timo
    Martikainen, Janne A.
    Soini, Erkki J. O.
    Kataja, Vesa
    Vuorinen, Riikka-Liisa
    Kellokumpu-Lehtinen, Pirkko-Liisa
    CLINICAL THERAPEUTICS, 2008, 30 (02) : 382 - 392
  • [12] Cabozantinib as a second-line treatment option in hepatocellular carcinoma
    D'Angelo, Alberto
    Sobhani, Navid
    Bagby, Stefan
    Casadei-Gardini, Andrea
    Roviello, Giandomenico
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (06) : 623 - 629
  • [13] Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety
    Merle, Philippe
    Kudo, Masatoshi
    Krotneva, Stanimira
    Ozgurdal, Kirhan
    Su, Yun
    Proskorovsky, Irina
    LIVER CANCER, 2023, 12 (02) : 145 - 155
  • [14] Cost-Effectiveness of Everolimus for Second-Line Treatment of Metastatic Renal Cell Carcinoma in Serbia
    Mihajlovic, Jovan
    Pechlivanoglou, Petros
    Sabo, Ana
    Tomic, Zdenko
    Postma, Maarten J.
    CLINICAL THERAPEUTICS, 2013, 35 (12) : 1909 - 1922
  • [15] CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma
    Albiges, Laurence
    Schmidinger, Manuela
    Taguieva-Pioger, Naila
    Perol, David
    Grunwald, Viktor
    Guemas, Eric
    FUTURE ONCOLOGY, 2022, 18 (08) : 915 - 925
  • [16] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Escudier, B.
    Powles, T.
    Mainwaring, P. N.
    Rini, B. I.
    Donskov, F.
    Hammers, H.
    Hutson, T. E.
    Lee, J-L
    Peltola, K.
    Roth, B. J.
    Bjarnason, G. A.
    Geczi, L.
    Keam, B.
    Maroto, P.
    Heng, D. Y. C.
    Schmidinger, M.
    Kantoff, P. W.
    Borgman-Hagey, A.
    Hessel, C.
    Scheffold, C.
    Schwab, G. M.
    Tannir, N. M.
    Motzer, R. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19): : 1814 - 1823
  • [17] Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis
    Pitt, M.
    Crathorne, L.
    Moxham, T.
    Bond, M.
    Hyde, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 41 - 46
  • [18] Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma
    Ueda, Kosuke
    Suekane, Shigetaka
    Hirano, Taishi
    Ogasawara, Naoyuki
    Chikui, Katsuaki
    Uemura, Keiichiro
    Nakiri, Makoto
    Nishihara, Kiyoaki
    Matsuo, Mitsunori
    Igawa, Tsukasa
    ANTICANCER RESEARCH, 2018, 38 (09) : 5387 - 5392
  • [19] Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
    Hoyle, Martin
    Green, Colin
    Thompson-Coon, Jo
    Liu, Zulian
    Welch, Karen
    Moxham, Tiffany
    Stein, Ken
    VALUE IN HEALTH, 2010, 13 (01) : 55 - 60
  • [20] Renal-cell carcinoma - current options for the second-line treatment with specific focus on the role of everolimus
    Wysocki, Piotr J.
    Zolnierek, Jakub
    Krzemieniecki, Krzysztof
    Drosik, Kazimierz
    Potemski, Piotr
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 (03): : 113 - 118
12345